News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    

Clinical - Phase I
Galapagos (GLPG.BR) Doses First Healthy Volunteer With CF Combo GLPG2222 And GLPG2451 2/24/2017
Why 2017 Will be a Data-Rich and Not Revenue-Focused Year for bluebird bio (BLUE) 2/24/2017
Symic Biomedical Announces Last Patient Enrolled In SHIELD Trial Of SB-030 For Interventions In Peripheral Artery Disease 2/24/2017
MabVax Therapeutics Announces FDA Authorization To Proceed With MVT-1075 In A Phase I Clinical Trial For The Treatment Of Pancreatic Cancer 2/23/2017
Zymeworks Submits ZW25 Phase 1 Clinical Study Findings Abstract For ASCO 2017 2/23/2017
Fibrocell (FCSC) Announces Dosing Of First Patient In Phase I/II Clinical Trial Of FCX-007 Gene Therapy For Treatment Of Recessive Dystrophic Epidermolysis Bullosa 2/23/2017
Acticor Biotech Has Selected Its Contract Research Organization To Manage Clinical Study Phase I 2/23/2017
CBT Pharma Presents Data Demonstrating Anti-Tumor Activity Of Its Programmed Death-1 Antibody, CBT-501, At ASCO-SITC Clinical Oncology Symposium 2/23/2017
Children’s National Health System Experts To Present Data On Novel Approach To Cell Therapy For Cancer Patients 2/23/2017
Inovio Reports New Positive Clinical Data On Vaccine Advances In The Fight Against Emerging Infectious Diseases 2/23/2017
The New England Journal of Medicine Publishes Phase Ib Results For Shire (SHPG)'s Investigational Treatment For Hereditary Angioedema, A Rare Genetic Disease 2/23/2017
Matrisys Bioscience Announces Today Publication Of Highly Promising Results Which Could Translate Into Clinically Meaningful Benefits For Eighteen Million Patients With Atopic Dermatitis 2/23/2017
ImmusanT, Inc. Announces Completion Of Phase Ib Clinical Trial Of Nexvax2 For The Treatment Of Celiac Disease 2/22/2017
Immune Design Corporation (IMDZ) Receives Orphan Drug Designation For G100 Intratumoral Product Candidate 2/22/2017
ChromaDex, Inc. Release: Study Published In PAIN Reveals Nicotinamide Riboside Is An Effective Tool In Relieving Chemotherapy-Induced Peripheral Neuropathy Induced By A Common Anticancer Agent 2/22/2017
Upon Successful Completion Of Cohort 3, Cellectar Biosciences  (CLRB) Initiates Fourth Cohort Of Its Phase I Clinical Trial Of CLR 131 In Multiple Myeloma 2/22/2017
Aethlon Medical (AEMD) Reports Results Of Cytomegalovirus, Epstein-Barr And Herpes Simplex Virus Studies 2/22/2017
Chimerix (CMRX) Announces Final Data From Advise Trial Of Brincidofovir At BMT Tandem Meetings 2/22/2017
MorphoSys AG's Subsidiary Lanthio Pharma Initiates First-in-Human Clinical Study With Lanthipeptide MOR107 2/21/2017
Halloran Consulting Group Advises SEEK In Preparation For First Trial Of Vaccine To Protect Against Mosquito-Borne Diseases, Including Zika And Malaria 2/21/2017
Bellicum (BLCM) Announces Initiation Of Patient Dosing With Controllable CAR T-Cell Product Candidate 2/21/2017
Protalex (PRTX) Provides Update On U.S. And EU Studies Of PRTX-100 To Treat Immune Thrombocytopenia 2/21/2017
hVIVO Services Limited Notes The Initiation Of A Phase I Clinical Trial With AGS-V, A Mosquito-Borne Disease Vaccine Candidate 2/21/2017
3 Biotechs With the Biggest and Most Promising Pipelines 2/20/2017
Nektar Therapeutics (NKTR) Release: Clinical Data From Phase I Dose-Escalation Study Of Single-Agent NKTR-214 In Patients With Renal Cell Carcinoma Presented At The ASCO 2017 Genitourinary Cancers Symposium 2/20/2017
Exelixis (EXEL) Announces Phase 1 Trial Results For Cabozantinib In Combination With Nivolumab With Or Without Ipilimumab In Refractory Metastatic Urothelial Carcinoma And Other Genitourinary Tumors 2/20/2017
Could Marijuana Be the Next Miracle Drug For Treating Cancer? 2/20/2017
Abeona Therapeutics Provides Update From ABO-102 Phase I/II MPS IIIA Clinical Trial At The 13th Annual WORLDSymposium 2017 2/17/2017
Theravance Biopharma (TBPH) Presents Positive Clinical Data On TD-1473 At The 12th Congress Of The European Crohn's And Colitis Organization 2/17/2017
Global Blood Therapeutics (GBT) Announces Initiation Of Phase I Trial To Evaluate The Physiologic Effects Of GBT440 In Healthy Volunteers Under Hypoxemic Conditions 2/17/2017
Capricor Therapeutics, Inc. Terminates Natriuretic Peptide Program Deal With The Mayo Clinic 2/17/2017
CoCrystal To Present Clinical Data On Its Potent Pan-Genotypic NS5B Non-Nucleoside Inhibitor CC-31244 At The Asian Pacific Association For The Study Of The Liver (APASL) Annual Meeting 2/17/2017
Noble Capital Markets Initiates Research Coverage On ESSA Pharma 2/17/2017
Alexion (ALXN) Stops Work on Early-Stage Sanfilippo B Drug, Takes a $85 Million Write Off 2/16/2017
Dauntless Pharma Announces Initiation Of Phase I Clinical Trial Of Octreotide Formulation For Intranasal Delivery 2/16/2017
Zymeworks Receives Second Orphan Drug Designation For ZW25 In Gastric Cancer 2/16/2017
Assembly Biosciences (ASMB) Announces Successful Completion Of ABI-H0731 Phase Ia Trial And Upcoming Conference Presentations 2/16/2017
Celyad Registers First Hematological Patient in CAR-T NKR-2 THINK Trial 2/16/2017
Berg Initiates Phase I/II Monotherapy Trial Of BPM 31510-IV In Patients With Glioblastoma Multiforme (GBM) 2/15/2017
ASLAN’ New ASLAN002 (BMS777607) Phase I Data Published In Science Translational Medicine 2/15/2017
Allergan (AGN) R&D Chief Reveals 6 Drugs That Could be Potential Blockbusters 2/14/2017
Aurinia (AUPH) Announces Results From Japanese Phase I Ethnic Bridging Study For Voclosporin 2/14/2017
Hutchison China MediTech (Chi-Med) Initiates First-In-Human Clinical Trial Of Novel FGFR Inhibitor HMPL-453 In Australia 2/14/2017
Allergy Therapeutics Announces Novel House Dust Mite Allergy Vaccine Gains Clinical Trial Application Approval 2/14/2017
Hutchison China MediTech (Chi-Med): Initiates Phase I Of Novel FGFR Inhibitor HMPL-453 2/14/2017
Progenics (PGNX) Announces Initiation Of A Phase I Clinical Trial Of Its PSMA-Targeted Therapeutic Candidate 1095 For The Treatment Of Metastatic Prostate Cancer 2/14/2017
Hutchison China MediTech (Chi-Med) Launches Phase I Trial Of Novel FGFR Inhibitor In Australia 2/14/2017
Vaxart Announces Positive Phase I Study Of Oral Norovirus Vaccine 2/14/2017
OncoMed (OMED) Enrolls First Patient In Phase Ib Clinical Trial Of Its Anti-DLL4/VEGF Bispecific Antibody In Patients With Platinum-Resistant Ovarian Cancer 2/13/2017
TRANSGENE (ENX:TNG) And Léon Bérard Cancer Center Announce Dosing Of The First Patient In A Phase 1 Immunotherapy Clinical Trial Evaluating The Intra-Tumoral Co-Administration Of Pexa-Vec Plus Ipilimumab (Yervoy) In Solid Cancers 2/13/2017
ASLAN Announces First Patient Enrolled In Phase l Study Of Varlitinib In Japan 2/13/2017
Prevacus To Begin Phase 1 Clinical Studies Of PRV-002 For The Treatment Of Concussion 2/10/2017
Ignyta (RXDX)'s Updated Phase 1 Data On Safety, Anti-Tumor Activity And CNS Activity Of Entrectinib In Cancers With TRK, ROS1 Or ALK Fusions Published In Cancer Discovery 2/9/2017
VM BioPharma Announces Publication Of Phase I/II Clinical Data Of Novel Gene Therapy VM202 In Amyotrophic Lateral Sclerosis (ALS) 2/9/2017
MeiraGTx Provides Clinical Trial Updates For Achromatopsia And Leber's Congenital Amaurosis Ocular Gene Therapy Programs 2/8/2017
Diffusion Pharma’ TSC Phase I/II Glioblastoma Multiforme Clinical Trial Results Published In February 2017 Edition Of Journal Of Neurosurgery 2/8/2017
No Looking Back: Cellectis (CLLS) Preps for Cutting-Edge 'Off-the-Shelf' CAR-T Trial 2/7/2017
GlaxoSmithKline (GSK)'s Incoming CEO Preps for Deals, R&D Decisions on New Drugs 2/7/2017
Vyome Announces Top-Line Results From Phase 1 Study Of VB-1953 For Patients With Facial Acne Vulgaris 2/7/2017
Actinium (ATNM.OB) Announces Pipeline Expansion With Initiation Of Clinical Trial Of Actimab-M In Multiple Myeloma 2/7/2017
These 5 Biotechs Are Battling Over the $10 Billion Hemophilia Market 2/6/2017
Spyryx Biosciences Announces Successful Completion Of Phase 1 Clinical Trial For SPX-101 And Planned Phase 2 Initiation In Cystic Fibrosis During 2017 2/6/2017
Auris Med (EARS) Expands Clinical Development Pipeline With Intranasal Betahistine For The Treatment Of Meniere's Disease And Vestibular Vertigo 2/6/2017
5 Daring Biopharmas Mixing Drugs With Marijuana 2/6/2017
Addex Therapeutics (ADXN.SW)' Clinical Programs And Discovery Platform Highlighted In Review Of Allosteric Modulators For The Treatment Of Neurodegenerative Diseases 2/6/2017
NASA Sent One Identical Twin Brother To Space And Studied How It Changed Him—Here Are The First Results 2/3/2017
bluebird bio (BLUE) Announces First Patient Treated With Lentiglobintm Drug Product Under Amended Study Protocol In HGB-206 Phase I Study Of Patients With Severe Sickle Cell Disease 2/3/2017
Lysogene Receives Orphan Drug Designation From FDA For LYS-GM101 For Treatment Of GM1 Gangliosidosis 2/3/2017
Phase I Clinical Data Of ABX464, ABIVAX's First-In-Class Anti-HIV Drug, Published In Two Articles In Peer-Reviewed Journals 2/3/2017
Bionomics Limited (BNO.AX) To Receive Milestone Payment From Merck & Co. (MRK) For Initiation Of Phase I Clinical Study Of Candidate Alzheimer's Treatment 2/3/2017
Auris Med (EARS) Expands Beyond Cochlear Therapies To Include Vestibular Therapy: Intranasal Betahistine, AM-125 2/3/2017
Pfizer (PFE) Quietly Kills 3 Pipeline Programs 2/2/2017
BioMarin (BMRN) Receives Access To Priority Medicines (PRIME) Regulatory Support From EMA For BMN 270 Gene Therapy In Hemophilia A 2/2/2017
Trillium Therapeutics Doses First Patient With TTI-621 In Phase 1 Solid Tumor Trial 2/2/2017
CytomX Announces The First Patient Treated In Phase I/II PROCLAIM-072 Trial 2/2/2017
Alnylam (ALNY) Presents New Data On Fitusiran At EAHAD 2/2/2017
Catabasis (CATB) Plunges on DMD Drug Trial Failure 2/1/2017
Cambridge's Dimension Therapeutics (DMTX) Tanks to a New Low After Revealing Interim Hemophilia B Data 2/1/2017
Abeona Therapeutics Enrolls First High Dose Subject In Ongoing Phase 1/2 Gene Therapy Clinical Trial In Sanfilippo Syndrome Type A 2/1/2017
Audentes (BOLD) Announces FDA Clearance Of Investigational New Drug Application For AT342 To Treat Crigler-Najjar Syndrome 2/1/2017
6 Biopharma Companies Face Catalysts in February 1/31/2017
Cellectar Biosciences  (CLRB) Announces Two Peer Reviewed Studies Demonstrating The Capabilities Of The PDC Platform 1/31/2017
DURECT (DRRX) Announces Update On DUR-928 Development Program 1/30/2017
EyeGate Pharma Announces Positive Top-Line Data From First-In-Human Pilot Trial Of Ocular Bandage Gel In Corneal Epithelial Defects 1/30/2017
X4 Pharma Release: Company Announces Initiation Of Clinical Study Of X4P-001 In Combination With Opdivo For Patients With Advanced Clear Cell Renal Cell Carcinoma 1/26/2017
Scientists Highlight the Hopes and Fears of Cellectis (ALCLS)' CAR-T 1/26/2017
SpinalCyte, LLC Enrolls First Patient In Landmark Phase I Human Clinical Trial 1/26/2017
Verastem (VSTM) Announces Dosing Of First Patient In Combination Trial Of Defactinib And Avelumab In Patients With Ovarian Cancer 1/26/2017
Neovia Oncology Release: Seattle Biotech Company Begins Clinical Trial For Immunotherapy Enhancing Cancer Drug 1/25/2017
Novartis AG (NVS) Shows Off 13 Potential Blockbusters in Pipeline 1/25/2017
ViraCyte Release: Company Receives Orphan Drug Designation For Viralym-C 1/24/2017
ProtoKinetix Inc. (PKTX.OB) Release: Company Announces Investigator Sponsored Human Clinical Trial Application Using AAGP Has Been Approved By Health Canada 1/24/2017
Asterias Biotherapeutics Release: Biotech Announces Additional Motor Function Improvement At 6-Months And 9-Months Following Treatment With AST-OPC1 In Patients With Complete Cervical Spinal Cord Injuries 1/24/2017
Sunesis (SNSS) Release: Biotech Announces Clinical And Regulatory Updates To SNS-062 And Vosaroxin Programs 1/23/2017
Resverlogix (RVX.TO) Release: Company Provides Groundbreaking Results In Patients With Severe Kidney Impairments 1/23/2017
Theravance Biopharma (TBPH) Release: Company Reports New Data From Ongoing TOUR Observational Patient Registry In Oral Presentation At SCCM Critical Care Congress 1/23/2017
GeoVax Labs Inc. (GOVX.OB) Release: Pharma Announces Initiation Of HIV Human Clinical Trial 1/23/2017
NantKwest Release: Landmark First-In-Human Clinical Study Launch Using A Genetically Engineered Natural Killer Cell For The Treatment Of Cancer 1/23/2017
OncoMed (OMED) Release: Company Initiates Enrollment Of Phase Ib Clinical Trial Of Brontictuzumab For The Treatment Of Metastatic Colorectal Cancer Patients 1/20/2017
ARMO BioSciences Release: Company Presents New Phase Ib Clinical Data For AM0010 In Advanced Pancreatic Cancer Patients At 2017 Gastrointestinal Cancers Symposium 1/20/2017
Infinity Pharma (INFI) Release: Company Presents Preclinical Data And Phase 1 Clinical Data On IPI-549 At PI3K Keystone Symposia Conference 1/20/2017
Abeona Therapeutics Release: Company Receives Orphan Drug Designation In The European Union For ABO-101 Gene Therapy In Sanfilippo Syndrome Type B 1/19/2017
Catabasis (CATB) Release: Company's Phase I Data On Edasalonexent (CAT-1004), A Potential Disease-Modifying Therapy Being Developed For Duchenne Muscular Dystrophy, Published In The Journal Of Clinical Pharmacology 1/19/2017
BioTime (BTX) Release: Additional Data From Company’s OpRegen Clinical Trial in Dry-AMD to be Presented At ARVO 2017 1/19/2017
Swedish Orphan Biovitrum Release: First Patients Enrolled In 24 Month Real-World Study Evaluating Effectiveness Of Elocta 1/19/2017
Lysogene Release: Biotech Receives Rare Pediatric Disease Designation From FDA For LYS-GM101 For Treatment Of GM1 Gangliosidosis 1/18/2017
WuXi AppTec Release: Novel Anti-IL-6 Antibody For Rheumatoid Arthritis From WuXi-MedImmune (AZN) Joint Venture Receives Clinical Trial Permit (CTP) From CFDA 1/18/2017
aTyr Pharma Release: FDA Grants Fast Track Designation For Company's Resolaris To Treat Limb Girdle Muscular Dystrophy 2B And Removes Partial Clinical Hold For Resolaris 1/18/2017
Daiichi Sankyo Release: Company Initiates Phase 1/2 Study Of Novel Antibody Drug Conjugate U3-1402 In Patients With HER3-Positive Metastatic Or Unresectable Breast Cancer 1/18/2017
Panacea Pharmaceuticals, Inc. Release: Company Initiates Phase I Study Of First-In-Class Cancer Vaccine Therapy Candidate In Patients With Persistent Prostate Cancer 1/17/2017
ProtoKinetix Inc. (PKTX.OB) Release: Company Announces Investigator Sponsored Clinical Trial Submitted To Health Canada For The Use Of AAGP In The Treatment Of Type 1 Diabetes 1/17/2017
JPM17: Why the Key to Gene Therapy Could be in an Old Bay Area Warehouse 1/16/2017
Hutchison China MediTech (Chi-Med) Release: Company Presents Phase I/II Clinical Data For Selective VEGFR Inhibitor Fruquintinib At The 2017 Gastrointestinal Cancers Symposium 1/16/2017
ObsEva Release: Company Announces Completion Of Phase I First-In-Women Study Of OBE022 For The Treatment Of Preterm Labor 1/13/2017
Celyad Release: Biotech Announces Registration Of The First Pancreatic Cancer Patient In Its CAR-T NKR-2THINK Trial In Belgium 1/12/2017
JPM17: Secretive Moderna Finally Unveils Pipeline, Financials 1/11/2017
Sangamo (SGMO) Release: Pharma Receives Orphan Drug Designation From The FDA For SB-318 Genome Editing Treatment For MPS I 1/11/2017
Bird Rock Bio Release: Biopharma Receives Approval To Start First In Human Clinical Trial For Namacizumab, Enters Into Agreement With GE Healthcare For Process Development And Scale-Up To Provide Clinical Phase 2 Cgmp Material, And Enters Into A Collaboration And Option Agreement With Janssen Pharmaceutical 1/11/2017
Affimed (AFMD) Release: Biopharma Provides Update On NK-Cell Immuno-Oncology Platform 1/11/2017
Corvus Pharma Announces Expansion Of Renal Cell Carcinoma Cohort In Ongoing Phase I/Ib Clinical Study Of Lead Checkpoint Inhibitor CPI-444 1/10/2017
ViraCyte Release: Pharma Granted U.S. FDA Fast Track Designation For Viralym-C 1/10/2017
Sangamo (SGMO) Release: Company Presents Latest Advances In Zinc Finger Nuclease Platform Technology At Keystone Symposium On Precision Genome Engineering 1/10/2017
Mologen (MOLGF.PK) Release: Grant To Collaboration Partner For Combination Study In HIV With Lead Product Lefitolimod 1/10/2017
Hutchison China MediTech (Chi-Med) Release: Company Initiates HMPL-523 Clinical Trials In Hematological Cancer In China 1/10/2017
BioMarin (BMRN) Release: Bay Area Biotech Solidifies Status as Top Dog in Hemophilia A Gene Therapy 1/10/2017
Sierra Oncology Successfully Transfers Sponsorship Of SRA737 Clinical Trials 1/9/2017
MabVax Therapeutics Files Investigational New Drug Application For Novel Radioimmunotherapy Agent MVT-1075 1/9/2017
Lexicon Pharma (LXRX) Begins Phase 1 Clinical Trial Of Locally-Acting SGLT1 Inhibitor, LX2761, For Potential Treatment Of Diabetes 1/9/2017
NeuroGenetic Pharmaceuticals, Inc. Completes Phase 1 Clinical Trials For NGP 555 To Treat And Prevent Alzheimer’s Disease; Shown As Safe And Well-Tolerated In Healthy Volunteers 1/9/2017
Tricida Announces Positive Topline Phase I/II Clinical Trial Results For TRC101 In 135 Subjects With Chronic Kidney Disease And Metabolic Acidosis 1/9/2017
Aridis Pharma Reports Positive Clinical Data From Phase 1/2a Study Of Human Monoclonal Antibody AR-301 For Treating Pneumonia 1/6/2017
CalciMedica Initiates Phase 1 Clinical Studies For CRAC Channel Inhibitor 1/6/2017
MacroGenics (MGNX)’ MGD006 Granted Orphan Drug Status For AML By FDA 1/6/2017
Chimerix (CMRX) Announces Preliminary Data From Ongoing Phase I Dose Escalation Study Of Intravenous Brincidofovir In Healthy Subjects 1/6/2017
Mirati Therapeutics  (MRTX) Provides Update On Glesatinib And Sitravatinib Clinical Trials And Pipeline Programs 1/6/2017
RedHill Biopharma (RDHL) Announces YELIVA (ABC294640) Abstract Presentation At The 2017 Cholangiocarcinoma Foundation Annual Conference 1/6/2017
Rgenix Announces Treatment Of First Patient In Phase 1 Trial Of RGX-104, Its Lead Immuno-Oncology Therapeutic 1/6/2017
TARIS Biomedical Announces Positive Results From Ph1b Trial Of TAR-200 (Gemristm) In Patients With Muscle Invasive Bladder Cancer 1/6/2017
Janssen Biotech (JNJ) Enters Immunotherapy Clinical Collaboration With Bristol-Myers Squibb (BMY) To Evaluate Daratumumab (DARZALEX) In Combination With Nivolumab (OPDIVO) 1/5/2017
Fibrocell (FCSC) Announces FDA Fast Track Designation Of FCX-007 For Treatment Of Recessive Dystrophic Epidermolysis Bullosa 1/5/2017
Fate Therapeutics (FATE) Announces First Patient Treated In Protmune PROTECT Clinical Trial For The Prevention Of Graft-Versus-Host Disease 1/5/2017
Zosano (ZSAN) Announces Last Subject Treated In Its Migraine Pivotal Trial 1/5/2017
Enterome Starts Phase I Clinical Trial With Its Lead Candidate EB8018 To Treat Crohn's Disease 1/5/2017
Seattle Genetics (SGEN) Initiates Phase I Trial Of SGN-CD352A For Patients With Relapsed Or Refractory Multiple Myeloma 1/5/2017
Minervax Announces Positive Results From Phase I Trial In 240 Healthy Adult Women With Its Innovative Group B Streptococcal (GBS) Vaccine To Prevent Life-Threatening Infections In Newborns 1/5/2017
Lycera Announces Initiation Of Phase 1/2a Study ARGON Of Immuno-Oncology Candidate LYC-55716 In Patients With Advanced Solid Tumors 1/4/2017
Rebiotix Treats First Patient In Phase 1 Study Of RBX7455, An Orally Delivered Broad-Spectrum Non-Frozen Microbiota Capsule For Recurrent Clostridium Difficile Infection 1/4/2017
OncoMed (OMED) Initiates Enrollment Of Phase Ib Clinical Trial Of Anti-DLL4/VEGF Bispecific Antibody As Second-Line Treatment For Metastatic Colorectal Cancer Patients 1/4/2017
Kura Oncology Receives FDA Clearance To Proceed With Clinical Trial For ERK Inhibitor KO-947 And Nominates KO-539 As Development Candidate For Menin-MLL Inhibitor Program 1/4/2017
Adamas Pharma (ADMS) Completes Phase I Clinical Trial Of ADS-4101 For Treatment Of Partial Onset Seizures In Patients With Epilepsy 1/4/2017
FDA Grants Fast Track Designation To Enanta Pharmaceuticals, Inc.’s FXR Agonist Candidate, EDP-305, For The Treatment Of NASH With Liver Fibrosis 1/4/2017
Asana Biosciences Announces Dosing Of First Patient In Phase I Trial Of ASN003, A Novel And Highly Selective B-RAF/PI3 Kinase Inhibitor 1/4/2017
Renowned Sinus Surgeon Dr. Peter-John Wormald Comments On AmpliPhi Bio (APHB)’ Favorable Phase I Results Of AB-SA01 In Chronic Rhinosinusitis Patients 1/4/2017
Glenmark Pharma Receives FDA Clearance Of IND For GBR 1302-BEAT Phase I Trial 1/3/2017
Ensysce Biosciences Inc. To Present Initial Phase 1 Data On Abuse Deterrent Opioid, PF614, At Biotech Showcase 2017 1/3/2017
Fortress Biotech (FBIO) Surged After Reporting Big Success With CAR-T Cancer Approach 12/30/2016
4 Fatal Deaths in Seattle Genetics (SGEN)' Early-Stage Trials of AML Drug 12/30/2016
Incyte (INCY) Announces First Patient Treated in Pivotal Clinical Trial Program for Ruxolitinib (Jakafi®) in Graft-versus-Host Disease 12/30/2016
Prima Biomed (PRR.AX) Announces First Clinical Data From Combination Of IMP321 With Anti-PD1 12/29/2016
ImmunoGen (IMGN) Announces Mirvetuximab Soravtansine Phase 1 Expansion Cohort Results In Platinum-Resistant Ovarian Cancer Published In The Journal Of Clinical Oncology 12/28/2016
BeiGene (BGNE) Doses First Patient In China Phase I PARP Trial 12/27/2016
Biohaven Enrolls First Patient In Pivotal Trial Of BHV-4157 In Patients With Hereditary Spinocerebellar Ataxia 12/22/2016
Provectus Announces Two Poster Presentations On PV-10 For Liver Tumors 12/22/2016
Bay Area’s CBT Pharma Plans to Launch 2 Phase I Trials in 2017 12/22/2016
Inovio Pharma (INO)’s Zika Vaccine Generates Robust Immune Responses In First Human Study 12/21/2016
Apellis Pharma Announces FDA Fast Track Designation For APL-2 In PNH 12/20/2016
MeiraGTx Granted Orphan Drug Designation For Its A004 Gene Therapy Treatment For Retinitis Pigmentosa 12/20/2016
AmpliPhi Bio (APHB) Reports Favorable Final Results From Phase 1 Trial Of AB-SA01 In Chronic Rhinosinusitis Patients 12/20/2016
Juno (JUNO)’ And Celgene (CELG)’s Investigational Drug JCAR017 Granted Breakthrough Therapy Designation From FDA And Priority Medicines Eligibility From EMAFor Relapsed/Refractory Diffuse Large B-Cell Lymphoma 12/20/2016
Astellas (ALPMY) Announces FDA Fast Track Designation For ASP0892, DNA Vaccine For Mitigation Of Severe Hypersensitivity Reactions Due To Peanut Allergy 12/20/2016
Tetra Discovery Partners Announces Positive Results From Phase 1 Studies Of Cognition Drug Candidate, BPN14770 12/19/2016
AmpliPhi Bio (APHB) Reports Favorable Final Results From Phase 1 Trial Of AB-SA01 In Chronic Rhinosinusitis Patients 12/19/2016
Spero Initiates First Clinical Study Of Lead Potentiator Candidate For The Treatment Of Multidrug Resistant Gram-Negative Infections 12/19/2016
Poxel SAS Announces Phase 1 Initiation Of EYP001 For The Treatment Of Chronic Hepatitis B Virus Infection By Licensing Partner Enyo Pharma 12/19/2016
DRGT's Novel Celecoxib Composition - Opportunity For Low Dose, Immediate Onset Of Pain Relief With The Only NSAID COX-2 Inhibitor On The Market 12/19/2016
New York’s Cellectis (ALCLS) Looks to 2017 for Clinical Trials of AML Treatment 12/16/2016
Enyo Pharma Announces Successful Initiation Of The Phase 1 Clinical Programme With EYP001, Its Lead Candidate For The Treatment Of Chronic Hepatitis B Virus Infection 12/16/2016
Alnylam (ALNY) Presents Initial 2017 Pipeline Goals At R&D Day With Focus On Alnylam 2020 Strategy 12/16/2016
Cellectis (ALCLS) Announces Recombinant DNA Advisory Committee’s (RAC) Unanimous Approval Of UCART123 Phase 1 Study Protocols In AML And BPDCN 12/16/2016
Investors Sigh With Relief as Biogen (BIIB)'s Alzheimer's Drug Delivers in Early-Stage Study 12/15/2016
BioPharm Executive: So Long 2016 (and Good Riddance?) 12/14/2016
Abide Therapeutics Announces First Patient Dosed In Phase 1b Study To Assess The Effect Of ABX-1431 In Patients With Functional Dyspepsia 12/14/2016
CytomX Announces U.S. FDA Clearance Of Investigational New Drug Application For Phase I/II Clinical Study Of Anti-PD-L1 Probody Therapeutic, CX-072 12/14/2016
Minoryx Therapeutics Receives European Orphan Drug Designation For Its Lead Candidate MIN-102 12/14/2016
Concert Pharmaceuticals, Inc. (CNCE) Announces CTP-543 Positive Top-Line Phase 1 Results 12/14/2016
SpinalCyte, LLC Receives Institutional Review Board Approval For Phase I Clinical Trial 12/14/2016
Zenith Epigentics Announces Initiation Of Phase 1b Clinical Combination Trial For ZEN-3694 12/14/2016
Addex Therapeutics (ADXN.SW) ADX71441 Pharmacological Profile Published In Neuropharmacology 12/13/2016
aTyr Pharma Reports Promising Signals Of Clinical Activity In Multiple Rare Genetically Distinct Myopathies With Resolaris In Exploratory Trials 12/13/2016
SCYNEXIS, Inc. (SCYX) Achieves New Development Milestones Reinforcing The Versatility Of SCY-078 In Treating Serious Fungal Infections 12/13/2016
Vyome Presents On The Development Of The Dual Action Rational Therapeutics Platform At The 2016 American Society of Microbiology Conference On Antibacterial Development 12/13/2016
3 Drugs Heading To The FDA Soon 12/12/2016
Eisai Inc. (ESALF.PK) Presents Data On BACE Inhibitor Elenbecestat (E2609) At 9th Clinical Trials On Alzheimer's Disease (CTAD) Meeting 12/12/2016
Tyme Completes The First Phase Of Its Prostate Cancer Clinical Study 12/12/2016
Edge Therapeutics Announces Publication Of Phase I/II Data On EG-1962 For The Treatment Of Aneurysmal Subarachnoid Hemorrhage In Peer-Reviewed Medical Journal, Stroke 12/12/2016
Cancer Targeted Technology Commences Phase I Clinical Trial Of CTT1057, A Diagnostic Imaging Agent For Prostate Cancer 12/12/2016
Seattle Genetics (SGEN) Highlights Phase 1 Data For Novel Antibody-Drug Conjugate SGN-LIV1A In Patients With Metastatic Breast Cancer At San Antonio Breast Cancer Symposium 12/12/2016
AXON Neuroscience’s Alzheimer Tau Vaccine Phase 1 Study Results Published In Lancet Neurology 12/12/2016
All Eyes Will Be on Biogen (BIIB) and Its Much-Anticipated Alzheimer's Data Tomorrow 12/9/2016
C2N Reports Phase I Study Results Of C2N-8E12 (ABBV-8E12) – Anti-Tau Antibody – In Subjects With Progressive Supranuclear Palsy 12/9/2016



//-->